- Details
- Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Mark Fleming, MD, GU Disease Committee Chair, Sarah Connon Research Institute, President, Virginia Oncology Association, Norfolk, VA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic U...
|
- Details
- Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Sumit K. Subudhi, Associate Professor, Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center,...
|
- Details
- Oliver Sartor joins Alicia Morgans are discussing the eagerly anticipated results from the PSMAfore study (NCT04689828), a phase three trial exploring PSMA-617 lutetium for taxane-naive patients with metastatic castrate-resistant prostate cancer (mCRPC). Notable findings from the study revealed significantly improved radiographic progression-free survival (rPFS) with PSMA-617 lutetium vs a change...
|
- Details
- Zach Klaassen and Ron Tutrone explore the promising data surrounding EPI-7386, an inhibitor of the androgen receptor. The conversation focuses on the phase two trial of EPI-7386 in combination with enzalutamide for treating metastatic castrate-resistant prostate cancer. Dr. Tutrone explains the unique mechanism of action of EPI-7386, which targets the N-terminal domain of the androgen receptors, u...
|
- Details
- Rashid Sayyid and Zach Klaassen, dissect a publication from the VISION study regarding health-related quality of life and pain outcomes with Lu-PSMA-617+ Standard of Care versus Standard of Care alone in patients with mCRPC. This study, conducted across 84 global centers, reveals that the addition of Lu-PSMA-617 to standard care significantly improved overall survival rates from 11.3 to 15.3 month...
|
- Details
- Phillip Koo interviews Ken Herrmann about his presentation focusing on a predictive model for 177Lu-PSMA-617. Herrmann explains the difference between a prognostic tool, which indicates a patient's overall prognosis, and a predictive tool that specifies whether a patient is likely to benefit from a particular therapy. He presents a model based on data from the Vision trial and explains how this mo...
|
- Details
- In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death. Despite...
|
- Details
- Alan Bryce joins Alicia Morgans in a discussion on the interim overall survival data from TRITON3, a Phase 3 study comparing rucaparib to physician's choice of therapy in metastatic castration-resistant prostate cancer associated with homologous recombination deficiency. Eligible patients had received at least one prior androgen receptor pathway inhibitor, were chemotherapy-naïve in the CRPC setti...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
- Details
- Neeraj Agarwal joins Alicia Morgans to discuss the TALAPRO-2 phase 3 trial, evaluating the combination of the PARP inhibitor talazoparib and enzalutamide versus enzalutamide and placebo as first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial included an all-comer population regardless of homologous recombination repair (HRR) gene mutations, and t...
|
